Novartis Dividends and Buybacks
Dividend criteria checks 5/6
Novartis is a dividend paying company with a current yield of 3.14% that is well covered by earnings.
Key information
3.1%
Dividend yield
3.1%
Buyback Yield
| Total Shareholder Yield | 6.2% |
| Future Dividend Yield | 3.3% |
| Dividend Growth | 4.7% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 66% |
Recent dividend and buyback updates
Recent updates
Narrative Update • Jun 06
NOVN: Broad Pipeline Data And Manufacturing Investments Will Support Balanced Outlook
Analysts have nudged their price target for Novartis higher from CHF 122.04 to CHF 123.55, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that collectively point to a slightly stronger long term outlook for the stock. What's in the News Pluvicto plus standard of care in PSMA positive metastatic hormone sensitive prostate cancer showed consistent radiographic progression free survival benefits across disease volume and presentation subgroups, along with supportive safety data, at ASCO 2026 and in the Phase 1 AcTION trial for actinium based RLT, reinforcing Novartis' radioligand therapy focus (source: Novartis, ASCO 2026).Narrative Update • May 21
NOVN: Expanded Therapies And Manufacturing Will Support Balanced Outlook And Dividend
Analysts have raised their Novartis price target slightly to CHF122.04 from CHF120.89, reflecting updated views on revenue growth, profit margins and the P/E multiple used in their models. What's in the News Pluvicto plus standard of care in the Phase III PSMAddition trial in PSMA positive metastatic hormone sensitive prostate cancer showed a 58% lower risk of PSA progression versus standard care alone, with a higher proportion of patients reaching deep PSA reductions at weeks 12, 24 and 48, and regulatory filings submitted in the US, China and Japan (Product related announcement).Narrative Update • Apr 27
NOVN: Pipeline Progress And Steady Dividend Will Support Balanced Future Outlook
Analysts now see slightly lower upside for Novartis, trimming their price target by around CHF 0.52. This reflects only marginal shifts in fair value, revenue growth, profit margin and future P/E assumptions.Narrative Update • Apr 11
NOVN: Dermatology And Immunology Pipeline Plus Dividend Will Shape Balanced Outlook
Analysts have slightly reduced their Novartis price target to CHF121.41 from CHF121.50. This change reflects updated assumptions that combine a somewhat lower revenue growth outlook with a modestly higher profit margin and a small adjustment to the future P/E multiple.Narrative Update • Mar 27
NOVN: Dermatology Pipeline, RLT Expansion And Dividend Will Shape Balanced Returns
Analysts have modestly raised their Novartis price target from CHF 117.49 to CHF 121.50, citing updated assumptions for revenue growth, profit margins and future P/E as key drivers of the revision. What's in the News Cosentyx received US FDA approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa, making it the only IL-17A inhibitor available for this group and expanding Novartis' dermatology footprint in a chronic inflammatory skin disease that often begins around puberty.Narrative Update • Mar 10
NOVN: Dividend Progress And US Manufacturing Expansion Will Shape Balanced Future Returns
Analysts have nudged their fair value estimate for Novartis up from about CHF116.24 to around CHF117.49. This mainly reflects slightly higher expected profit margins and a modestly higher future P/E assumption, while revenue growth expectations are a touch lower.Narrative Update • Feb 23
NOVN: Autoimmune Pipeline Readouts And Dividend Growth Will Shape Balanced Future Returns
Analysts have raised their Novartis price target from CHF 113.58 to CHF 116.24. This reflects updated assumptions that combine slightly higher revenue growth with a modestly lower profit margin and a higher future P/E multiple.
New Narrative • Feb 17
Radioligand And Gene Therapy Platforms Will Support A Stronger Long Term Outlook
Catalysts About Novartis Novartis is a global pharmaceutical company focused on patented medicines across oncology, cardiovascular, immunology, neuroscience and gene therapy. What are the underlying business or industry changes driving this perspective?Narrative Update • Feb 09
NOVN: US Infrastructure Buildout And Autoimmune Pipeline Will Shape Balanced Future Returns
Analysts have nudged their fair value estimate for Novartis up from $110.20 to $113.58, citing updated assumptions around modestly higher revenue growth, slightly stronger profit margins, and a marginally lower future P/E multiple. What's in the News Canada's Drug Agency issued a positive draft recommendation to reimburse Kisqali ribociclib tablets for eligible high risk early breast cancer patients, following Health Canada approval in June 2025 and Phase III data indicating reduced risk of recurrence across a broad HR+/HER2- stage II-III population (Key Developments).Analysis Article • Feb 08
Novartis (VTX:NOVN) Has Announced That It Will Be Increasing Its Dividend To $3.70
Novartis AG ( VTX:NOVN ) will increase its dividend from last year's comparable payment on the 12th of March to $3.70...Analysis Article • Feb 07
Novartis AG (VTX:NOVN) Full-Year Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for Novartis AG ( VTX:NOVN ) shareholders, because the company has just released its latest...Narrative Update • Jan 25
NOVN: US Buildout And Late-Stage Autoimmune Pipeline Will Shape Future Returns
Analysts now set their Novartis price target at about $110.20, up slightly from roughly $110.00. This reflects small tweaks to assumptions around long term revenue growth, profit margins and future P/E expectations.Narrative Update • Jan 11
NOVN: Future Returns Will Reflect US Buildout And Late-Stage Pipeline Delivery
Analysts have raised their price target for Novartis to $109.99 from $106.64, citing updated assumptions for slightly stronger revenue growth, higher profit margins, and a modestly lower future P/E multiple. What's in the News Novartis plans a new 35,000 square foot radioligand therapy manufacturing facility in Winter Park, Florida, as part of its previously announced US$23b US investment.Narrative Update • Dec 25
NOVN: Future Returns Will Reflect US Investment And Pipeline Execution Under Stable Outlook
Analysts have modestly reduced their price target on Novartis to approximately $107 per share from about $109. This reflects slightly lower margin expectations that more than offset improved revenue growth assumptions under an unchanged risk profile.Narrative Update • Dec 10
NOVN: Future Returns Will Reflect Pipeline Progress And Expanding US Manufacturing
Analysts have modestly raised their price target on Novartis to approximately $109 from about $105. This change reflects a higher expected future valuation multiple, which more than offsets slightly lower long term revenue growth and profit margin assumptions.Narrative Update • Nov 26
NOVN: Future Outlook Will Balance New Approvals And Expanding US Operations
Narrative Update on Novartis Novartis’ analyst price target has been revised upward from $102.12 to $104.58. This change reflects modest adjustments in fair value and expectations based on analysts’ latest evaluations of the company’s growth and profitability outlook.Analysis Article • Nov 09
We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative
Even though Novartis AG's ( VTX:NOVN ) recent earnings release was robust, the market didn't seem to notice. Investors...Narrative Update • Nov 02
NOVN: Future Trial Data And Pipeline Advancements Will Support Steady Returns
Analysts have raised their fair value estimate for Novartis from $98.60 to $102.12. They cite improved revenue growth outlook and stronger profit margins as key drivers of the upward revision.Narrative Update • Oct 17
China Expansion And Advanced Therapies Will Drive Future Upside
Analysts have slightly reduced their price target for Novartis to $98.60 from $99.08, as they cite marginally lower expectations for future revenue growth and profit margins. What's in the News CHMP of the European Medicines Agency recommended marketing authorization for Scemblix (asciminib) for all lines of treatment in adults with chronic myeloid leukemia, based on positive Phase III data.Narrative Update • Oct 03
China Expansion And Advanced Therapies Will Drive Future Upside
Analysts have raised their fair value estimate for Novartis from $97.49 to $99.08. They cite improved revenue growth projections, even though profit margin expectations have decreased slightly.Narrative Update • Sep 17
China Expansion And Advanced Therapies Will Drive Future Upside
Novartis's future P/E multiple has materially contracted even as consensus revenue growth forecasts edged up, resulting in a marginal decrease in fair value from CHF99.36 to CHF97.49. What's in the News Novartis and Argo Biopharmaceutical entered a strategic collaboration on multiple cardiovascular assets, granting Novartis ex-China licensing and P&L options on several siRNA pipeline compounds; Argo received $160M upfront, with milestones and royalties potentially totaling up to $5.2B.Analysis Article • Aug 01
These 4 Measures Indicate That Novartis (VTX:NOVN) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jun 18
Novartis AG (VTX:NOVN) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 17.8x Novartis AG ( VTX:NOVN ) may be sending bullish signals at the...Stability and Growth of Payments
Fetching dividends data
Stable Dividend: NOVN's dividends per share have been stable in the past 10 years.
Growing Dividend: NOVN's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Novartis Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (NOVN) | 3.1% |
| Market Bottom 25% (CH) | 2.0% |
| Market Top 25% (CH) | 3.7% |
| Industry Average (Pharmaceuticals) | 2.8% |
| Analyst forecast (NOVN) (up to 3 years) | 3.3% |
Notable Dividend: NOVN's dividend (3.14%) is higher than the bottom 25% of dividend payers in the Swiss market (2%).
High Dividend: NOVN's dividend (3.14%) is low compared to the top 25% of dividend payers in the Swiss market (3.72%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (66.3%), NOVN's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (52.5%), NOVN's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/08 17:42 |
| End of Day Share Price | 2026/06/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novartis AG is covered by 55 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |
| Gerhard Schwarz | Baader Helvea Equity Research |